Literature DB >> 15052530

Ghrelin/Leptin-imbalance in patients with primary biliary cirrhosis.

M Breidert1, T F Zimmermann, R Schneider, G Ehninger, G Brabant.   

Abstract

BACKGROUND: The recently discovered peptide hormone ghrelin mainly produced in gastric oxyntic cells may act as a counterpart to leptin in the regulation of food intake and fat utilization. Leptin, involved in the stimulation of proinflammatory cytokines and catabolic energy balance, is elevated in patients with liver cirrhosis. In the present study, we evaluated serum ghrelin and bound leptin levels in patients with primary biliary cirrhosis (PBC) in relation to C-peptide and glucose concentration.
METHODS: In 22 female patients with PBC (Child-Pugh stage A) and in 36 female controls we measured serum ghrelin, bound leptin, and C-peptide levels using specific immunoassays.
RESULTS: In comparison to controls serum bound leptin levels were significantly higher in patients with PBC ( p < 0.01) whereas serum ghrelin levels were decreased compared to the control group ( p < 0.01). In parallel, C-peptide concentrations were increased ( p < 0.01) with no significant change in circulating glucose levels.
CONCLUSION: Our data confirm in PBC patients that serum bound leptin levels are increased and clearly show a parallel decrease in serum ghrelin concentrations acting as a physiological counterpart to leptin. Furthermore, we suggest that these changes are linked to the insulin resistance observed in our patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15052530     DOI: 10.1055/s-2004-817819

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  9 in total

Review 1.  Fatigue in primary biliary cirrhosis.

Authors:  Ghulam Abbas; Roberta A Jorgensen; Keith D Lindor
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-05-11       Impact factor: 46.802

2.  Leptin Enhances Hepatic Fibrosis and Inflammation in a Mouse Model of Cholestasis.

Authors:  Anca D Petrescu; Stephanie Grant; Elaina Williams; Su Yeon An; Nikhil Seth; Mark Shell; Tyson Amundsen; Christopher Tan; Yusra Nadeem; Matthew Tjahja; Lancaster Weld; Christopher S Chu; Julie Venter; Gabriel Frampton; Matthew McMillin; Sharon DeMorrow
Journal:  Am J Pathol       Date:  2021-12-08       Impact factor: 4.307

3.  Predictive and Diagnostic Value of Serum Adipokines in Pregnant Women with Intrahepatic Cholestasis.

Authors:  Nazan Yurtcu; Canan Soyer Caliskan; Huri Guvey; Samettin Celik; Safak Hatirnaz; Andrea Tinelli
Journal:  Int J Environ Res Public Health       Date:  2022-02-16       Impact factor: 3.390

Review 4.  Osteoporosis in liver disease: pathogenesis and management.

Authors:  Gabriela Handzlik-Orlik; Michał Holecki; Krzysztof Wilczyński; Jan Duława
Journal:  Ther Adv Endocrinol Metab       Date:  2016-04-06       Impact factor: 3.565

5.  Fasting and postprandial plasma ghrelin levels are decreased in patients with liver failure previous to liver transplantation.

Authors:  Maria Teresa Diz-Lois; Jesús Garcia-Buela; Francisco Suarez; Susana Sangiao-Alvarellos; Ovidio Vidal; Fernando Cordido
Journal:  Endocrine       Date:  2009-04-11       Impact factor: 3.633

Review 6.  Osteoporosis in primary biliary cirrhosis of the liver.

Authors:  Joanna Raszeja-Wyszomirska; Tomasz Miazgowski
Journal:  Prz Gastroenterol       Date:  2014-05-05

Review 7.  Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression.

Authors:  Ming-Ling Chang; Zinger Yang; Sien-Sing Yang
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

8.  Serum Ghrelin Concentration in Patients With Primary Biliary Cirrhosis (PBC).

Authors:  Rania Naguib; Amel Fayed; Eman Elkemary; Hend Naguib
Journal:  Cureus       Date:  2021-12-09

9.  Ghrelin reverses ductular reaction and hepatic fibrosis in a rodent model of cholestasis.

Authors:  Anca D Petrescu; Stephanie Grant; Elaina Williams; Gabriel Frampton; Evan H Reinhart; Amy Nguyen; Suyeon An; Matthew McMillin; Sharon DeMorrow
Journal:  Sci Rep       Date:  2020-09-29       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.